- Home
- NTIP vs RNXT Comparison
NTIP vs RNXT Comparison
Compare NTIP & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- RNXT
- Stock Information
- Founded
- NTIP 1990
- RNXT 2012
- Country
- NTIP United States
- RNXT United States
- Employees
- NTIP N/A
- RNXT N/A
- Industry
- NTIP Multi-Sector Companies
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- RNXT Health Care
- Exchange
- NTIP Nasdaq
- RNXT Nasdaq
- Market Cap
- NTIP 32.9M
- RNXT 33.8M
- IPO Year
- NTIP 1998
- RNXT 2021
- Fundamental
- Price
- NTIP $1.38
- RNXT $1.50
- Analyst Decision
- NTIP
- RNXT Strong Buy
- Analyst Count
- NTIP 0
- RNXT 2
- Target Price
- NTIP N/A
- RNXT $6.50
- AVG Volume (30 Days)
- NTIP 62.9K
- RNXT 101.2K
- Earning Date
- NTIP 03-07-2025
- RNXT 11-13-2024
- Dividend Yield
- NTIP 7.25%
- RNXT N/A
- EPS Growth
- NTIP N/A
- RNXT N/A
- EPS
- NTIP N/A
- RNXT N/A
- Revenue
- NTIP $1,881,000.00
- RNXT N/A
- Revenue This Year
- NTIP N/A
- RNXT N/A
- Revenue Next Year
- NTIP N/A
- RNXT N/A
- P/E Ratio
- NTIP N/A
- RNXT N/A
- Revenue Growth
- NTIP 129.39
- RNXT N/A
- 52 Week Low
- NTIP $1.22
- RNXT $0.77
- 52 Week High
- NTIP $2.25
- RNXT $1.86
- Technical
- Relative Strength Index (RSI)
- NTIP 51.53
- RNXT 64.78
- Support Level
- NTIP $1.33
- RNXT $1.26
- Resistance Level
- NTIP $1.47
- RNXT $1.60
- Average True Range (ATR)
- NTIP 0.07
- RNXT 0.12
- MACD
- NTIP -0.00
- RNXT 0.01
- Stochastic Oscillator
- NTIP 43.75
- RNXT 72.22
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property rights. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.